Healthcare, Pharma & Life Sciences

Bonn – November 05, 2026 -- CDU/CSU health policy spokesperson Simone Borchardt says the planned Pflegeneuordnungsgesetz (Care Reorganization Act) should channel existing funds more precisely rather than add spending, and she has not ruled out benefit cuts in individual cases.

Borchardt rules out more money for care structures that are up to 50 years old

In an interview with broadcaster phoenix, Borchardt, who speaks on health policy for the CDU/CSU parliamentary group in the Bundestag, said the state cannot keep pouring more money into the care system. In some areas, she said, the system is 40 or 50 years old. She called for modern, effective structures and for money to be invested in a more targeted way.

Benefit cuts possible in individual cases, but not the focus

Borchardt said individual cases could see reduced benefits under the reform. She stressed that cuts should not be the focus of the legislation.

Wayne, Pa. – November 05, 2026 -- HUSK, a preventative wellness technology company serving self-funded and fully insured employers and health insurers, has launched HUSK Wellness, an ecosystem that combines five benefits and gives employers reporting on whether wellness spend reduces healthcare costs.

HUSK Wellness bundles five benefits into one personalized employee journey

The platform covers Challenge, Rewards, Marketplace, Nutrition and Mental Health. Each employee's journey is shaped by employer goals and driven by employee choice. Onboarding is led by Poppie, HUSK's wellness assistant, which learns each employee's goals, interests and preferences and builds a path across all five benefits.

Chicago – November 05, 2026 -- More than 100 sponsor-backed provider services assets are now over six years into their initial hold period, creating pressure for exits as investor interest returns to the sector, according to Brown Gibbons Lang & Company (BGL).

The investment bank's Healthcare & Life Sciences team said in a new industry report that market recovery in provider services remains well below historical highs. Signs of a thaw are emerging, however, after a prolonged slowdown through 2025 and into 2026.

Four drivers are renewing investor appetite for provider services

BGL attributes the renewed interest to a combination of factors:

Berlin – November 05, 2026 -- Germany's pharmaceutical lobby BPI says the country's healthcare system is neither crisis-proof nor crisis-resilient, as external shocks collide with structural weaknesses in both the industry base and patient supply. BPI Managing Director Dr. Kai Joachimsen made the assessment at the FORUM-Institut's annual health policy conference, "Pharma Trends 2027".

Joachimsen lists five pressure points behind the "polycrisis"

He cited trade conflicts, a dependence on Asia that is still tending to grow despite repeated warnings, fragile supply chains, cyberattacks, and scarce, expensive energy and raw materials.

Joachimsen argued that policy has not matched the threat level. In his view, health policy is location policy and must now also function as security policy.

Boston – November 05, 2026 -- Haemonetics Corporation (NYSE: HAE) has published its second-quarter fiscal 2027 results for the period that ended September 26, 2026, and will discuss them with investors and analysts on a call at 8:00 a.m. ET on November 5, 2026.

Haemonetics posts earnings release and supplemental presentation online

The company placed two documents on its Investor Relations website: the Second Quarter Fiscal 2027 Earnings Release and the Second Quarter Fiscal 2027 Supplemental Earnings Presentation. Management will reference both during the call. The announcement does not disclose revenue, earnings or guidance figures, which are contained in the posted materials.

Melbourne – November 05, 2026 -- Telix Pharmaceuticals has joined Thera4Care, a 27-partner European consortium, and its FAP-targeting dimer DOTAGA.Glu.(FAPi)2 will enter a Phase 1 trial labelled with terbium-161 (161Tb) in metastatic solid tumors.

Consortium picks Telix's FAP dimer for a Phase 1 trial with terbium-161

The trial will assess the safety profile and preliminary activity of 161Tb-DOTAGA.Glu.(FAPi)2 in patients with FAP-expressing metastatic solid tumors. The initial focus is ovarian cancer, pancreatic cancer and sarcomas. Telix says this aligns closely with its own development plans for TLX400-Tx, the lutetium-177 (177Lu) version of the same compound. The dimer has already been validated in several clinical studies.

BOSTON – November 05, 2026 -- Attuned Intelligence has launched Attuned Coverage, an AI voice and chat tool for Medicaid applications and renewals, with OCHIN becoming the first health care network to offer it to member organizations that care for more than 8.7 million people.

OCHIN selects Attuned as preferred partner across 2,400 sites

OCHIN, a nonprofit that supports more than 47,000 clinicians across over 2,400 rural and community-based delivery sites, named Attuned a preferred partner. Lynn Community Health Center, an OCHIN member in Massachusetts, was the lead adopter. Its frontline staff helped shape the product around the needs of enrollment teams and patients.

HONG KONG – November 05, 2026 -- Fosun has used its ninth consecutive China International Import Expo (CIIE) appearance to debut Intuitive Surgical's da Vinci 5 robotic system in China. It also reported that its Intuitive Fosun joint venture has trained more than 23,000 doctors across 33 training centers. This year's expo in Shanghai draws participants from 162 countries, regions and international organizations, with more than 4,100 corporate exhibitors.

Fosun is exhibiting at the Fosun Pharma booth (2.1C4-01) in the Medical Equipment and Healthcare Products Exhibition Area. Its displays cover oncology, immunology and inflammation, and neurodegenerative diseases. Fosun International Chairman Guo Guangchang described the CIIE as "an annual test of our global industrial and innovation capabilities."

Shanghai – November 05, 2026 -- Dizal (SSE: 688192) will present three oral and five poster presentations from its hematological disease portfolio at the 68th American Society of Hematology (ASH) Annual Meeting, including the first clinical data for its EZH1/2 inhibitor GW5282 in relapsed or refractory non-Hodgkin lymphoma (r/r NHL).

Golidocitinib data extend from lymphoma into secondary HLH

An oral presentation will report updated results for golidocitinib monotherapy in adults with secondary hemophagocytic lymphohistiocytosis (HLH). The data extend findings shown at the European Hematology Association (EHA) Congress 2026. Dizal reports high and durable response rates with a manageable safety profile, which it says supports further development in the indication.

BLOOMFIELD, Conn. – November 05, 2026 -- The Cigna Group raised its 2026 outlook for adjusted income from operations to at least $30.60 per share after third-quarter revenues rose 6% to $73.7 billion, driven by growth in both Evernorth Health Services and Cigna Healthcare.

Adjusted earnings edge up while net income falls on a year-earlier gain

Adjusted income from operations was $2.1 billion, or $7.98 per share, against $7.83 per share in the third quarter of 2025. Shareholders' net income fell to $1.4 billion, or $5.47 per share, from $1.9 billion, or $6.98 per share, because the prior-year period included an after-tax gain on sale. Cigna said adjusted income was stable year on year, as growth in Cigna Healthcare and Specialty and Care Services offset a lower contribution from Pharmacy Benefit Services.